Triplet Immunosuppression for Immune Checkpoint Inhibitor-Related Adverse Events is Associated With High Infection Risk.
BACKGROUND The use of multiagent immunosuppressive therapy (IST) to treat immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) increases the risk of infection. Time-normalized infection rates in a large cohort have not been previously reported. Predictors of opportunistic and nonopportunistic...